29.52
Avidity Biosciences Inc stock is traded at $29.52, with a volume of 3.28M.
It is down -6.58% in the last 24 hours and down -3.66% over the past month.
See More
Previous Close:
$31.60
Open:
$30.1
24h Volume:
3.28M
Relative Volume:
2.52
Market Cap:
$4.00B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-10.21
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
-11.35%
1M Performance:
-3.66%
6M Performance:
-35.73%
1Y Performance:
+15.67%
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RNA
Avidity Biosciences Inc
|
29.52 | 4.00B | 10.12M | -280.49M | -188.51M | -2.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-13-25 | Initiated | Citigroup | Buy |
Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
Dec-20-24 | Initiated | H.C. Wainwright | Buy |
Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
Sep-24-24 | Initiated | Goldman | Buy |
Aug-28-24 | Initiated | Barclays | Overweight |
May-03-24 | Initiated | BofA Securities | Buy |
Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
Jul-12-22 | Initiated | Raymond James | Strong Buy |
Sep-07-21 | Initiated | Evercore ISI | Outperform |
Jun-17-21 | Initiated | Needham | Buy |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Jul-07-20 | Initiated | Cowen | Outperform |
Jul-07-20 | Initiated | Credit Suisse | Outperform |
Jul-07-20 | Initiated | SVB Leerink | Outperform |
Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - PR Newswire
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com India
The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha
Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia
Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia
Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise
Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia
Avidity Biosciences CFO Michael MacLean sells $246,424 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $365,867 in stock - Investing.com
Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com
Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView
Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com
Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nasdaq
Avidity Biosciences Signals Growth: Awards 152K Shares to 16 New Hires - Stock Titan
H.C. Wainwright maintains $72 target on Avidity Biosciences stock By Investing.com - Investing.com Canada
Forecasting The Future: 13 Analyst Projections For Avidity Biosciences - Benzinga
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Yahoo
New Duchenne Results Put Avidity On Course For Filing - insights.citeline.com
Avidity Biosciences reports progress in DMD treatment trial By Investing.com - Investing.com Australia
Citi maintains $70 target on Avidity Biosciences stock post-trial By Investing.com - Investing.com Canada
Avidity eyes 2025 BLA on back of positive DMD data - BioWorld Online
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 - Benzinga India
Avidity Biosciences Shares Tumble Despite Trial Success - TipRanks
Avidity Biosciences reports progress in DMD treatment trial - Investing.com India
Avidity Biosciences Announces Positive EXPLORE44 Trial Results - TipRanks
Avidity Biosciences Announces Positive Topline Del-Zota Data In DMD44 Trial -March 17, 2025 at 07:12 am EDT - Marketscreener.com
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skip - Financial Times
Bank of New York Mellon Corp Buys 59,295 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
BMO Capital Markets Begins Coverage on Avidity Biosciences (NASDAQ:RNA) - Defense World
Citigroup Initiates Coverage of Avidity Biosciences (RNA) with Buy Recommendation - Nasdaq
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - The Malaysian Reserve
Avidity Biosciences Stock Climbs Amid Promising Prospects - TipRanks
Avidity Biosciences’s SWOT analysis: RNA therapy pioneer’s stock poised for growth By Investing.com - Investing.com South Africa
BMO Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform Recommendation - MSN
Avidity Biosciences chief scientific officer sells $602,614 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences Announces Upcoming Presentations at the Musc - GuruFocus.com
Avidity Biosciences chief scientific officer sells $602,614 in stock - Investing.com India
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference – Company AnnouncementFT.com - Financial Times
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Benzinga India
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Avidity Biosciences to Participate in Upcoming Investor Conferen - GuruFocus.com
BMO starts coverage on Avidity with 'outperform', says first-in-disease therapies in sight - TradingView
BMO Capital Initiates Avidity Biosciences at Outperform With $72 Price Target -March 12, 2025 at 07:10 am EDT - MarketScreener
Avidity Biosciences’s SWOT analysis: RNA therapy pioneer’s stock poised for growth - Investing.com India
BMO CAPITAL INITIATES AVIDITY BIOSCIENCES WITH OUTPERFORM RATING By Investing.com - Investing.com UK
Avidity Biosciences (NASDAQ:RNA) Price Target Cut to $48.00 by Analysts at Bank of America - Defense World
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):